In a filing, Oncology Institute Inc revealed its Director M33 Growth I L.P. unloaded Company’s shares for reported $18.6 million on Sep 04 ’25. In the deal valued at $3.09 per share,6,018,168 shares were sold. As a result of this transaction, M33 Growth I L.P. now holds 7,932,389 shares worth roughly $30.06 million.
Then, M33 Growth I L.P. sold 681,832 shares, generating $2,106,861 in total proceeds. Upon selling the shares at $3.09, the Director now owns 590,892 shares.
Before that, Hively Brad sold 20,221 shares. Oncology Institute Inc shares valued at $82,097 were divested by the Director at a price of $4.06 per share. As a result of the transaction, Hively Brad now holds 622,980 shares, worth roughly $2.36 million.
Noble Capital Markets initiated its Oncology Institute Inc [TOI] rating to an Outperform in a research note published on July 23, 2025; the price target was $8. A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who began to cover the stock in mid July with a ‘”a Buy”‘ rating. BTIG Research began covering TOI with “Buy” recommendation on May 15, 2025.
Price Performance Review of TOI
On Friday, Oncology Institute Inc [NASDAQ:TOI] saw its stock fall -3.07% to $3.79. Over the last five days, the stock has gained 4.12%. Oncology Institute Inc shares have risen nearly 1110.86% since the year began. Nevertheless, the stocks have risen 1126.54% over the past one year.
How much short interest is there in Oncology Institute Inc?
A steep rise in short interest was recorded in Oncology Institute Inc stocks on 2025-09-30, dropping by -0.73 million shares to a total of 5.1 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 5.83 million shares. There was a decline of -14.39%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 14, 2022 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $7 price target.
